Wed, Jul 30, 2014, 5:16 AM EDT - U.S. Markets open in 4 hrs 14 mins

Recent

% | $
Click the to save as a favorite.

Boston Scientific Corporation Message Board

  • timber_look_out_below timber_look_out_below Sep 2, 2005 3:37 PM Flag

    MORE CRASHING FOR BSX NEXT WEEK

    Downgrades on the way. Insiders will sell more. Debt will grow. Institutions will dump.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • BSX is a death factory, all they seem to do is injure and kill patients with their defective junk. How many people have died now?

    • I'm sure the huge debt, failed products, etc and the cost of recalls is going to hit the bottom line, so they want out by getting suckers to buy on hype while they dump, but I think the real reason they want out so bad is because they know that EECP and alternative technologies are catching on and it will put an end to BSX.
      BSX only real product is totally obsolete. Its history say night night.

      Doctors have cut into Theodore Dippy's heart twice to clear clogged arteries, other times they attempted to sweep aside blockages with tiny balloons, and once left a metal stent inside an artery to keep it propped open, after going through numerous heart procedures he finally found relief with a little known treatment that involves sqeezing the legs in large cuffs to propel more blood to the heart. The nonsurgical approach, called Enhanced External Counterpulsation, has been found by studies to provide a significant reduction in chest pains and blockages. The low tech treatment is carried out during one hour sessions while the patient lies on a padded table, with 3 large cuffs on each leg.
      Dippy's doctor, cardiologist Ken Kronhaus, has treated more than 600 patients with EECP.
      Today, doctors throughout the U.S. offer the treatment at prestegious medical centers, including the Mayo Clinic, and the Cleavland Clinic, have centers for the procedure.
      Researchers have been able to document the improved blood flow by doing heart scans on patients before and after treatment to look for changes. Medicare recently began paying for the procedure. Other insurers also cover the procedure. Doctors who offer the therapy see a trend toward its greater use.

    • What a laugh. October 14th. It might as well be 1999.

      JNJ is scared to death of what is going to happen to them in the cath lab.

      'rump

    • Selling this stock was one of the smartest things I've done. They will lose the class action suits, and continue to lose money as more and more competitors take market share, and stent prices fall. The FDA will probably do the right thing and pull Taxus and stop the deaths, its surprising to me that any doctors would use Taxus at this point theres so many injuries resulting from its use that they should be afraid of malpractice suits for using defective devices. They are already losing money, as prices fall things will get worse.
      Boston Scientific Reports $269M Loss in 3Q
      Friday October 14, 5:17 pm ET
      By Mark Jewell, AP Business Writer
      Boston Scientific Reports $269 Million 3Q Loss , Dip in Coronary Stent Sales

      BOSTON (AP) -- Boston Scientific Corp. on Friday acknowledged it has lost ground to medical device rivals in the lucrative market for drug-coated heart stents, reporting a $269 million third-quarter loss and slowing sales of a stent.

      The performance, fell short of Boston Scientific's projection and Wall Street's expectations.

      "We still think that management might be too optimistic and that earnings estimates still need to be lowered."

      Morgan Stanley said the challenge for Boston Scientific in the coming quarters will be holding off market share losses as Johnson & Johnson (nyse: JNJ - news - people )expands capacity and Medtronic (nyse: MDT - news - people ) introduces Endeavor in Europe.

      "As we look to future, we still see some downside relative to stent market share, market size and estimated margins. We should also point out that there is little in place (with respect to the pipeline)

    • This is a disaster all right, its a bankruptcy waiting to happen. Where there is smoke there is fire. Why do you think insiders are not buying?

    • Good comment.
      '
      There is an amazing amount of transparent agenda nonesense out there.

      Mostly, axes to grind, IMO.

      I think the Guidant bid is sstrategic action at its best, and hope they succeed.

      A shareholder.

      specsit

    • Actually, the most amazing thing is that they ARE using their brains. They really see what they are doing as clever. I just noticed they are also recommending their own posts multiple times.

      For the regular posters here, this is just so completely lame and transparent, AND unintelligent. Like when one of the aliases who has been extremely negative in post after post says something like, "I hope we can hold at $22, but if we break that support....." As if they ever hoped anything but their stunning elementary agenda.

      Much like commercials for weight loss pills that work when you sleep, or the Sauna Belt, etc., it only makes me more shocked at the stupidity of some humans.

      CYD

    • "Please shoot yourself losser."

      Amen, Bro!

      Need any help, Timber, Shirley, Politicaldebate, Crispy, Stinky, or whatever the hell is you primary alias?

    • Probably more JNJ tactics. They are putting pressure on BSX where ever they can. I think the term is ghost writing. They have the Wall Street Journal and technical publications doing this as well. Repeat BS. Sad part is that some poor fools are biting.

    • couldn't have said it better myself.....thank you

    • View More Messages
 
BSX
12.89-0.08(-0.62%)Jul 29 4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.